Abstract Submission Guidelines

1. These guidelines are exclusively applied to non-Japanese ophthalmologists living outside of Japan who would like to submit abstracts as "international members".
2. Those who want to submit abstracts have to create a user account.
3. Once the submission is completed, an automatic notification will be sent to the registered e-mail address to confirm your abstract registration.If you do not receive the e-mail within 60minutes after the submission, please check on the website if you have entered the correct e-mail address.If you still do not receive an e-mail, please contact the congress secretariat at ringan2017@congre.co.jp.
4. You may make a change to the abstract or withdrawal after submission until the due date.Please log into your own page with your ID and password.Please note that each abstract has an abstract number which is necessary for change or withdrawal.

Application for General Presentation (Paper / Poster)

1. Please choose your presentation style from;

   Free Paper presentation

   Computer-based presentation only (film slides or videotapes are not allowed)

   Poster presentation

   Discussion in the Poster/Exhibition Hall

2. Please choose an appropriate category from the following list;

• ※Please note that the presentation style you chose for your presentation may be changed to the other presentation style due to the reviews by the committee.
• ※More than one application from the same author as the first presenter should not be accepted.None of the abstracts may be accepted when more than one application from the same first author is suspected.

Applicant’s Qualification

The first author (presenter) of a general presentation should be an international member of the Japanese Ophthalmological Society.Non-members at the time of application are eligible to submit an application and will be granted international membership after acceptance of abstract, endorsement from the presidents and approval by the Board.For further information on international membership, please see here.

Notification of Receipt of Abstracts

To confirm receipt of the abstract, notification will be automatically sent to the registered e-mail address.If you do not receive the notification at the registered e-mail address within 60 minutes, please check if you have entered the correct e-mail address.Should you still have the problem please contact the congress secretariat.For submissions (general presentations), notification of acceptance or rejection will be sent to the registered e-mail address around July, 2017 (tentative).

Guidelines for Abstract Preparation

1. Papers that have been presented or will be presented in any other academic meetings in Japan cannot be accepted.Papers that have been published in Japan cannot be accepted either.
2. The first author of the general presentation cannot be the first presenter of any other general presentation.
3. Title of the abstract should be no longer than 80 characters and the body of the abstract should be no longer than 1200 characters.The shortened title should be no longer than 30 characters.Affiliation should be concise.Please note that the above-mentioned number of characters include spaces.
4. The abstract should contain Objective, Subjects and Methods, Results, and Conclusions, in that order.For case reports and invention or improvement of technics and devices, please change the headings appropriately (for example, for case reports, Introduction, Cases, Discussion and if relevant, Conclusions).
5. Methods, Results, etc.should be described clearly, with numerical values and the statistical analysis methods used, where possible.Invention or improvement of techniques and devices should be clearly described.
6. The Conclusion and Discussion should correspond to the Results described.
7. Common names should be used for chemicals.Trade names should be given (……®) after the common names, if necessary (Example: timolol maleate [Timoptol®]).
8. Presentations, abstracts and presentation data should be prepared in English.
9. Declaration of conflict of interests is mandatory for author (presenter) and co-authors (co-presenters) (See below for details).
10. Please select whether you have obtained an approval of the ethics committee, e.g.IRB, or if it is not necessary on the abstract submission form.The author is not required to mention it in the abstract text.
11. Please select whether you have obtained an informed consent or if it is not necessary on the abstract submission form.The author is not required to mention it in the abstract text.

Appendix

1. When a duplicate submission (presentation) is suspected, please contact the Committee for Judging Duplicate Presentations of the Japanese Ophthalmological Society in advance.
2. When a duplicate submission (presentation) is confirmed after the registration deadline, presentations by the author (presenter) and co-authors (co-presenters) of the abstract may be temporarily suspended. Furthermore, their names may be published in the official Journal of Japanese Ophthalmological Society.
3. The content of the abstract and its description are equally evaluated by peer review and revisions are not allowed after the registration deadline.
4. When the presentation includes part of the research conducted by multiple institutions, agreement of the persons concerned should be obtained in advance, and the content of the agreement should be described in the abstract text.
5. Meaningless rhetoric, prefixes (for example, Mr., Ms., Prof. and Dr.) inappropriate for academic papers, should not be used.
6. Abstracts without data in the Results section, such as those that only state “will be investigated” and “we describe…,” may be rejected.
7. Conclusions should not be drawn from any content(s) that are not described in the Results.
8. The number of authors is not limited. However, if the number is 13 or more, please contact the congress secretariat in advance.
9. Withdrawal and revision after the registration deadline are not allowed under any circumstances.
10. If a presenter does not make a presentation at the designated time and place without prior notice, a penalty will be imposed to the presenter who will not be allowed to make a presentation as the first presenter in the next meeting. This policy was laid down by the Program Committee of the Japanese Ophthalmological Society. If unable to attend the meeting for any compelling reason on the designated day and time, the presenter must inform the congress secretariat promptly and submit a statement of reasons for absence by letter or e-mail (ringan2017@congre.co.jp) by the end of the meeting.

Conflict of Interest

When making a presentation at the Annual Meeting of the Japanese Ophthalmological Society and the Annual Congress of Japan Clinical Ophthalmology, the authors have to report any conflict of interest based on "the rules for conflict of interest of Japanese Ophthalmological Society." If the presentation is accepted, the category of conflict of interest and the names of the companies must be disclosed in the presentation slide and poster, based on "the rules for conflict of interest of Japanese Ophthalmological Society."

A.Presentations to Which These Rules are Applicable

These rules are applicable to all presentations including those in Co-Sponsored Seminars, Special Lectures, Invited Lectures, Symposia (including ARVO-JOS Symposium), Instruction Courses, General Presentations (including posters) and so on.

B.Reports on Conflict of Interest

Report on the potential conflict of interest with companies within the last three years no matter whether it's concerned with or without the content of your presentation is required.If conflict of interest is "present, " enter the category and the names of the companies in the entry field of "Conflict of Interest" on the abstract submission form.The answer will be submitted automatically to the Japanese Ophthalmological Society.

Categories and classes are as follows.

1.Category

F (Financial Support)：

In the case where research expenses are supported or free research materials (including devices) or services (including sample measurements) are provided by companies (*) through the organization to which the author belongs.
(*) Companies denote both related companies and competitor companies.This is also the case for all subsequent categories.

I (Personal Financial Interest):

In the case where the author is an investor in a company related to the chemicals and materials (including devices).

E (Employee):

In the case where the author is an employee of an interested company.

C (Consultant):

In the case where the author is currently, or was within the past three years, a consultant of an interested company.

P (Patent):

In the case where the author holds a patent or is in the process of applying for a patent.

R:

In the case where the author receives rewards (*) or travel expenses from a company related to the chemicals and materials (including devices) used and services provided.
(*) Rewards include salaries, travel fees, intellectual property rights, royalties, honoraria, shares, stock options, consultancy fees, lecture fees, expenses as a member of advisory committees and review panels, etc.

2.Class

1.   0 yen
2.  From 1 to less than 500,000 yen
3. From 500,000 to 5,000,000 yen
4. Over 5,000,000 yen

*Conflict of interest should be disclosed for the fiscal year during the previous three years when the author received the largest sum of money.

Disclosure in the Abstract and Slide

1.Abstract:

Presence or absence of conflict of interest to be disclosed for the author (including co-authors) will be shown at the end of the abstract according to "the detailed rules of the standard for disclosure in the Japanese Ophthalmological Society." For categories F, C and R, only class IV (over 5,000,000 yen) will be correspond to "presence".Category and the names of the companies will not be shown in the abstract.

2.Slide and poster:

If the authors have to disclose any conflict of interest, the category and the names of the companies should be described after the authors' names in the second slide and at the end of the poster (for category P, the names of the companies need not to be mentioned).For categories F, C and R, only class IV (over 5,000,000 yen) should be disclosed.
If none of the authors has any conflict of interest to be disclosed, there will be a statement to the effect "there is no conflict of interest to be disclosed".
Please contact the congress secretariat for any questions by e-mail or FAX (not by telephone).

Congress Secretariat
c/o Congress Corporation
E-mail:ringan2017@congre.co.jp　Tel: +81-3-5216-5318

Personal Information Protection

Personal information such as "names" and "contact addresses" provided to us at registration shall be used for the purpose of contact from the secretariat, notification of acceptance or rejection, and any other information related to the presentation.In addition, the "presenters' names, " "affiliation names, " "presentation title" and "abstract text" shall be used for publication in the program/proceedings and on the website, but not for other purposes.The registration process for applications has been commissioned to c/o Congress Corporation in order to facilitate management operations.

【Inquiries】
Congress Secretariat
c/o Congress Corporation
E-mail: ringan2017@congre.co.jp　Tel: +81-3-5216-5318